Figure 6. Splicing-neoantigen cell of origin is dependent on its mechanism of regulation.

A,B) Venn diagrams comparing the number of parental neojunctions for TCGA SKCM splicing neoantigens unique to a single-patient (A) or shared in >15% of patients (B) to the specific cell-types they derive from in independent melanoma tumor biopsies by single-cell RNA-Seq analysis. Neojunctions are defined as tumor or immune if they are >2 fold enriched in either cell-population (absolute number of reads in all patients and cells for each lineage). C) Neojunction expression in individual cell populations for select shared splicing neoantigens. Each dot denotes the combined neojunction read counts in a single patient (n=19) with melanoma, separately per cell annotated cell population.